AAV

In gene therapy, viral vectors, in which pathogenicity is artificially excluded, play an important role in delivering therapeutic genes to tissues and cells. As adeno-associated virus (AAV) vectors are relatively safe due to their non-pathogenic nature and exhibit various tissue tropisms, they have been actively researched and developed as gene therapy vectors by pharmaceutical companies and start-up companies in recent years. Following its approval in Europe in 2012 as a treatment of lipoprotein lipase deficiency, AAV gene therapy products have also been approved in recent years for spinal muscular atrophy and hereditary retinal dystrophy. In gene therapy using AAV vectors, it is crucial for the therapeutic genes to be delivered to the target tissues or cells to ensure both efficacy and safety.

 

Takara Bio is actively developing AAV vectors for gene therapy that exhibit high tissue specificity for specific tissues through collaborations with universities and public research institutions. As part of our research efforts, we have successfully developed AAV vectors with enhanced targeting capabilities for brain and inner ear tissues. We are actively advancing the development of gene therapies using these vectors, while also providing AAV vectors through CDMO services to support the translation of gene therapy into practical applications in society.

In brain-targeted gene therapy, AAV vectors injected intravenously tend to accumulate in organs other than brain, such as liver, and therefore it has been suggested that high doses may cause adverse reactions. To overcome this problem, highly brain-directed AAV vectors are needed for brain-targeted gene therapy. We succeeded in developing CereAAV^TM, a novel AAV vector for gene therapy, which was derived from AAV2 through genetic engineering and unique screening techniques and has a highly brain-targeted tropism. In mice, CereAAV^TM showed gene transduction to the brain by intravenous injection more efficiently than AAV9, the conventional gene used for gene therapy. In cynomolgus monkeys, a primate more closely related to humans, CereAAV^TM showed more efficient gene transduction than AAV2 and AAV9 in several brain regions.

 

A collaborative research with Tokyo Metropolitan Institute of Medical Science, revealed that CereAAV^TM demonstrated more efficient gene transduction by intravitreal injection into mouse retinal cells compared to AAV2. Currently, AAV vector based gene therapy approved for ocular disease requires highly invasive subretinal injection. Therefore, there is a need for AAV vectors that can efficiently transduce genes into retinal cells by simple intravitreal injection. We have been developing CereAAV^TM for clinical use of gene therapy for brain and ocular diseases.

 

We provide contract manufacturing services for various viral vectors, including AAV vectors.
We also provide CDMO services for CereAAV^TM series including the modified vectors.

 

[For the details of CDMO services]
https://www.takarabio.com/services-and-support/gene-and-cell-therapy-manufacturing/services

Recently, AAV gene therapy has also been developed for hereditary hearing loss. However, the gene transduction efficiency of conventional AAV vectors to the inner ear is not sufficient to demonstrate therapeutic efficacy. We have also developed a novel AAV vector, SonuAAV^TM, which exhibits high gene transfer efficiency into mouse inner ear tissues, in collaboration with Juntendo University. In this study, we found that local injection of SonuAAV^TM into mouse inner ear efficiently delivers genes to the target tissues for gene therapy. Moreover, we also demonstrated that SonuAAV^TM expressing GJB2 gene can improve the hearing in adult Gjb2-deficient mice 6 week after local injection. We have also developed SonuAAV^TM-based gene therapy for hereditary hearing loss.